Avricore Health Inc. (AVCRF)
OTHER OTC:AVCRF
Want to see AVCRF full AI Analyst Report?
AVCRF Stock Chart & Stats
$0.03
<$0.01(0.26%)
At close: 4:00 PM EST
$0.03
<$0.01(0.26%)
Day’s Range― - ―
52-Week Range$0.02 - $0.08
Previous CloseN/A
Volume61.00K
Average Volume (3M)60.67K
Market Cap
$4.68M
Enterprise Value$6.56M
Total Cash (Recent Filing)$541.75K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.85
Next Earnings
May 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding101,289,665
10 Day Avg. Volume71,961
30 Day Avg. Volume60,671
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)13.00
Price to Sales (P/S)9.49
P/FCF Ratio-5.77
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue3.41
Enterprise Value/Gross Profit7.86
Enterprise Value/Ebitda-11.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pharmacy-based POC Testing PlatformAvricore's business model sells both services and platform capabilities to community pharmacies, creating multiple revenue levers (per-test, platform fees, program contracts). That diversified service+software model supports recurring program revenue and scalable site expansion if partnerships grow.
Multiple Program Revenue StreamsThe company's revenue mix (test delivery fees, platform/service revenue, and program contracts) creates varied monetization channels and reduces single-source dependency. Durable contractual program revenues and platform services can improve predictability and margin as scale increases.
Conservative Leverage, Low DebtEffectively zero debt lowers fixed interest costs and funding risk, giving management flexibility to support operations, invest in platform development, or pursue partnerships without immediate solvency pressure. This enhances resilience through cyclical revenue volatility.
Bears Say
Sharp TTM Revenue DeclineA near-40% TTM revenue drop and deep negative margins materially reduce the company's ability to realize operating leverage from its decent gross margin. Sustained declines erode scale, compress cash generation, and make it harder to fund platform development or expand pharmacy programs.
Cash-flow Volatility And Recent FCF BurnThe swing from positive FCF in 2024 to a TTM cash burn signals unstable cash generation. Persistent or recurring negative free cash flow would force external financing or cutbacks, constraining investments in sales execution and platform enhancements needed to regain growth.
Eroding Equity And Negative ROEFalling shareholder equity and a very negative ROE reflect cumulative losses that can limit strategic flexibility. Continued erosion increases likelihood of dilutive capital raises, harms investor returns, and weakens the balance sheet's ability to absorb further operational setbacks.
Avricore Health News
AVCRF FAQ
What was Avricore Health Inc.’s price range in the past 12 months?
Avricore Health Inc. lowest stock price was $0.02 and its highest was $0.08 in the past 12 months.
What is Avricore Health Inc.’s market cap?
Avricore Health Inc.’s market cap is $4.68M.
When is Avricore Health Inc.’s upcoming earnings report date?
Avricore Health Inc.’s upcoming earnings report date is May 28, 2026 which is in 21 days.
How were Avricore Health Inc.’s earnings last quarter?
Currently, no data Available
Is Avricore Health Inc. overvalued?
According to Wall Street analysts Avricore Health Inc.’s price is currently Overvalued.
Does Avricore Health Inc. pay dividends?
Avricore Health Inc. does not currently pay dividends.
What is Avricore Health Inc.’s EPS estimate?
Avricore Health Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avricore Health Inc. have?
Avricore Health Inc. has 101,289,665 shares outstanding.
What happened to Avricore Health Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avricore Health Inc.?
Currently, no hedge funds are holding shares in AVCRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avricore Health Inc.
Avricore Health Inc. engages in the health data and point-of-care technologies business in Canada. It provides HealthTab, a lab-accurate point of care testing platform for pharmacy. The company has strategic partnerships with Shoppers Drug Marts and Abbott. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.
Technical Analysis
BioMark Diagnostics
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
―
PanGenomic Health, Inc. Class A
―
Ownership Overview
Options Prices
Currently, No data available
---